Abstract
In this issue of Blood, Jo et al1 provide compelling evidence in a mouse model that enhanced activity of the linear ubiquitin chain assembly complex (LUBAC) can drive B-cell lymphomagenesis and may offer a new therapeutic target for the activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL).
Original language | English (US) |
---|---|
Pages (from-to) | 646-647 |
Number of pages | 2 |
Journal | Blood |
Volume | 136 |
Issue number | 6 |
DOIs | |
State | Published - Aug 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology